Cyproterone Acetate

Subscribe to Selected New Research on Cyproterone Acetate

697 relevant articles (58 outcomes, 112 trials/studies) found for this Bio-Agent

Description: An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.

Also Known As:

Androcur; Cyproterone Acetate, (1 alpha,2 alpha)-Isomer; Cyproterone Acetate, (1 alpha,2 alpha,9 beta,10 alpha)-Isomer; Cyproterone Acetate, (17 alpha)-Isomer; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 58

Cyproterone Acetate: 697

Diane: 16

climen: 5

15-hydroxycyproterone acetate

17-hydroxycyproterone acetate

3 alpha-hydroxy-cyproterone acetate

Chlorinated Steroids

Cyproterone: 50

Cyproterone Acetate: 697

Diane: 16

climen: 5

15-hydroxycyproterone acetate

17-hydroxycyproterone acetate

3 alpha-hydroxy-cyproterone acetate

Experts

1.	Escobar-Morreale, Héctor F: 2 articles (07/2008 - 07/2007)
2.	Alvarez-Blasco, Francisco: 2 articles (07/2008 - 07/2007)
3.	Luque-Ramírez, Manuel: 2 articles (07/2008 - 07/2007)
4.	Tapanainen, J S: 2 articles (02/2005 - 09/2000)
5.	Morin-Papunen, L C: 2 articles (02/2005 - 09/2000)
6.	Ruokonen, A: 2 articles (02/2005 - 09/2000)
7.	de Vries, C S: 2 articles (07/2004 - 03/2003)
8.	Farmer, R D T: 2 articles (07/2004 - 03/2003)
9.	Seaman, H E: 2 articles (07/2004 - 03/2003)
10.	Spitzer, Walter O: 2 articles (06/2004 - 12/2003)

Related Diseases

1.	Hirsutism 01/01/1990 - "Cyproterone acetate given as a single intramuscular dose of 300 mg monthly for 6 months resulted in significant reduction of hirsutism without appreciable side effects" 01/01/2003 - "The major outcomes included: subjective improvement in hirsutism, changes in Ferriman Gallwey scores, changes in linear hair growth and hair shaft diameter, alterations in endocrine parameters, side effects to treatment, withdrawals during therapy MAIN RESULTS: There were no clinical trials comparing cyproterone acetate alone with placebo" 11/01/1978 - "The administration of cyproterone acetate can be effective in the treatment of 'idiopathic' hirsutism" 07/01/1991 - "Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study." 01/01/1987 - "In the present study a parenteral treatment regimen with cyproterone acetate was compared with the high dose peroral administration in patients with severe hirsutism" Get all the results and reference details, order at left...
2.	Acne Vulgaris 01/01/2006 - "In this study we evaluated the efficacy of cyproterone acetate alcohol lotion (CAAL) in the treatment of the mild to moderate acne vulgaris" 01/01/2006 - "The efficacy of topical cyproterone acetate alcohol lotion versus placebo in the treatment of the mild to moderate acne vulgaris: a double blind study." 01/01/2006 - "Regarding the results of this study, we suggest the use of cyproterone acetate alcohol lotion as one of the main treatments for mild-moderate acne in female patients and as an adjuvant treatment for moderate to severe acne vulgaris." 01/01/2004 - "A COC with cyproterone acetate might result in better acne outcomes than one with desogrestrel; however, the three studies comparing these COCs produced conflicting results" 04/01/1998 - "Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial." Get all the results and reference details, order at left...
3.	Prostatic Neoplasms (Prostate Cancer) 04/29/2000 - "INTERPRETATION: In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%." 07/01/2003 - "Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer]" 06/01/1980 - "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial." 05/04/2007 - "Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer" 12/14/2006 - "Cyproterone acetate (CPA) is a steroidal synthetic progestagen and anti-androgenic compound widely administered in prostate cancer which has been evidentially correlated with a severe hepatotoxic potency" Get all the results and reference details, order at left...
4.	Alopecia (Baldness) 01/01/1989 - "The therapeutic results warrant the conclusion that cyproterone acetate seems to be effective in androgenetic alopecia in women." 01/01/1989 - "The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females." 12/01/2002 - "We report a 66-year-old lady taking 50 mg/day of cyproterone acetate for biopsy proven androgenetic alopecia, who developed this unusual complication of shortness of breath" 12/01/2002 - "Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia." 06/01/2002 - "Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial." Get all the results and reference details, order at left...
5.	Neoplasms (Cancer) 02/01/2008 - "Cyproterone acetate (CPA), a synthetic progestin is not only a genotoxic agent but also a tumor initiating agent" 12/01/2005 - "Disappearance of a virilizing adrenal tumor following therapy with cyproterone acetate." 06/04/2004 - "The anti-androgen and progestagen cyproterone acetate (CPA) is known to cause liver tumors in rats" 05/01/2001 - "In agreement with these considerations the regulatory authorities of the European Union came to the common conclusion that a possible cancer risk associated with the clinical use of cyproterone acetate, if any, appears to be low and the risk-benefit ratios for the currently authorised indications remain favourable." 10/01/1996 - "When the tumor size was about 10 mm, animals were subcutaneously administered cyproterone acetate (0.1 mg/day and 0.8 mg/day) or solvent alone for 21 days" Get all the results and reference details, order at left...
132 Diseases and 697 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ethinyl Estradiol (Estinyl)
2.	Spironolactone (Aldactone)
3.	Flutamide (Eulexin)
4.	Estradiol (Estrace)
5.	Gonadotropin-Releasing Hormone (GnRH)
6.	Estrogens (Estrogen)
7.	Finasteride (Propecia)
8.	Androgen Antagonists (Antiandrogens)
9.	Testosterone (Sustanon)
10.	Androgen Receptors (Androgen Receptor)
218 Drugs and Important Bio-Agents and 440 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Castration
3.	Orchiectomy (Orchidectomy)
4.	Drug Therapy (Chemotherapy)
5.	Prostatectomy (Retropubic Prostatectomy)
13 Therapies and Procedures and 72 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>